RECRUITING

The Effects of Specialty Coffee on Cognitive Function in People With Type 2 Diabetes

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Coffee has been found to have beneficial effects on cognitive function and blood sugar control. Benefits include reduced risk of cognitive decline and improved performance on cognitive tests, as well as reduced risk of diabetes and improved blood sugar control in people with diabetes, a population that is at a higher risk of cognitive decline. These effects have been observed for both caffeinated and decaffeinated coffee, and have been associated with the polyphenol chlorogenic acid (CGA). This polyphenol has been found to be more bioavailable in certain coffees, known as "speciality coffee" as defined by the Specialty Coffee Association of America, depending on agriculture, roasting, and brewing method. This current project will bring together these previous findings to explore the effects of specialty coffee on cognitive function and glycaemic control in people with type 2 diabetes through a randomized control trial with two groups: a high CGA specialty coffee group and a conventional coffee control group. Participants will be quasi-randomly assigned to one of these two groups following the completion of a 4-week run-in period during which participants will consume conventional coffee only. The length of the experimental arms is 8 weeks, therefore the total length of the study is 12 weeks. At the beginning and the end of each experimental arm participants will undertake a cognitive assessment online using the Gorilla platform, and a series of questionnaires relating to health and mood measures (details in procedure). Cognitive function will also be assessed at the beginning of the 4-week run-in period.

Official Title

The Effects of CGA-rich Coffee on Cognitive Function in Type 2 Diabetes: A Parallel Groups Randomised Controlled Trial

Quick Facts

Study Start:2023-01-01
Study Completion:2025-01-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05709847

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:55 Years to 70 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 55-70 years
  2. * Formal diagnosis of Type 2 Diabetes for 3 years or more
  3. * Current coffee drinkers, 4 or fewer cups daily (a cup is 8 oz)
  1. * Insulin-dependent
  2. * Consuming on average more than 4 cups of coffee daily
  3. * Regularly consuming specialty coffee (participants will be provided with a list of these coffees)

Contacts and Locations

Study Contact

Daniel J Lamport, PhD
CONTACT
+44 (0)1183785032
daniel.lamport@reading.ac.uk

Principal Investigator

Daniel Lamport, PhD
PRINCIPAL_INVESTIGATOR
University of Reading

Study Locations (Sites)

Kaiser Permanente
Berkeley, California, 94710
United States

Collaborators and Investigators

Sponsor: University of Reading

  • Daniel Lamport, PhD, PRINCIPAL_INVESTIGATOR, University of Reading

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-01
Study Completion Date2025-01-01

Study Record Updates

Study Start Date2023-01-01
Study Completion Date2025-01-01

Terms related to this study

Additional Relevant MeSH Terms

  • Type 2 Diabetes